Drugs / 68Ga-JH04
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT06455735 | Mar 2024 → Dec 2025 | neoplasm | First Affiliated Hospital of Fujian Medical University | Unknown | No outcome recorded |
| Phase 0 | NCT06438250 | Mar 2024 → May 2025 overdue | cancer | First Affiliated Hospital of Fujian Medical University | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 68Ga-JH04 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06455735 ↗ |
| Modality | Diagnostic / imaging agent | “As a novel radiotracer targeting fibroblast activation protein (FAP), 68Ga-JH04 is promising as an excellent imaging agent for various cancers.” NCT06455735 ↗ |
| Route | Intravenous | “The dose will be 148-222 MBq given intravenously.” NCT06438250 ↗ |